Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD

Juan F. Burgueno, Adrian Reich, Hajar Hazime, Maria A. Quintero, Irina Fernandez, Julia Fritsch, Ana M. Santander, Nivis Brito, Oriana M. Damas, Amar Deshpande, David H. Kerman, Lanyu Zhang, Zhen Gao, Yuguang Ban, Lily Wang, Judith Pignac-Kobinger, Maria T. Abreu

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Background: Patients with inflammatory bowel disease (IBD) have intestinal inflammation and are treated with immune-modulating medications. In the face of the coronavirus disease-19 pandemic, we do not know whether patients with IBD will be more susceptible to infection or disease. We hypothesized that the viral entry molecules angiotensin I converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are expressed in the intestine. We further hypothesized that their expression could be affected by inflammation or medication usage. Methods: We examined the expression of Ace2 and Tmprss2 by quantitative polymerase chain reacion in animal models of IBD. Publicly available data from organoids and mucosal biopsies from patients with IBD were examined for expression of ACE2 and TMPRSS2. We conducted RNA sequencing for CD11b-enriched cells and peripheral and lamina propria T-cells from well-annotated patient samples. Results: ACE2 and TMPRSS2 were abundantly expressed in the ileum and colon and had high expression in intestinal epithelial cells. In animal models, inflammation led to downregulation of epithelial Ace2. Expression of ACE2 and TMPRSS2 was not increased in samples from patients with compared with those of control patients. In CD11b-enriched cells but not T-cells, the level of expression of ACE2 and TMPRSS2 in the mucosa was comparable to other functional mucosal genes and was not affected by inflammation. Anti-tumor necrosis factor drugs, vedolizumab, ustekinumab, and steroids were linked to significantly lower expression of ACE2 in CD11b-enriched cells. Conclusions: The viral entry molecules ACE2 and TMPRSS2 are expressed in the ileum and colon. Patients with IBD do not have higher expression during inflammation; medical therapy is associated with lower levels of ACE2. These data provide reassurance for patients with IBD.

Original languageEnglish (US)
Pages (from-to)797-808
Number of pages12
JournalInflammatory bowel diseases
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2020

Keywords

  • Coronavirus
  • Crohn disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Fingerprint Dive into the research topics of 'Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD'. Together they form a unique fingerprint.

  • Cite this

    Burgueno, J. F., Reich, A., Hazime, H., Quintero, M. A., Fernandez, I., Fritsch, J., Santander, A. M., Brito, N., Damas, O. M., Deshpande, A., Kerman, D. H., Zhang, L., Gao, Z., Ban, Y., Wang, L., Pignac-Kobinger, J., & Abreu, M. T. (2020). Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD. Inflammatory bowel diseases, 26(6), 797-808. https://doi.org/10.1093/ibd/izaa085